NewGLAB Pharma Competitors and Similar CompaniesClear all

NewGLAB Pharma's competitors and similar companies include Zydus Lifesciences, Medochemie, King Pharmaceuticals and Interbat.

	NewGLAB Pharma NewGLAB Pharma is a company engaged in the pharmaceutical, surveillance, and distribution businesses.	Zydus Lifesciences Zydus Lifesciences (formerly known as Cadila Healthcare) is a company that provides healthcare solutions.	Medochemie Medochemie is a pharmaceutical company.	King Pharmaceuticals King Pharmaceuticals is a pharmaceutical company that develops, manufactures, markets, and sells branded prescription pharmaceutical products.	Interbat Interbat is a pharmaceutical company.
Founding Date	Founding Date 2004	Founding Date 1952	Founding Date 1976	Founding Date 1993	Founding Date 1948
Type	Type Public	Type Public	Type Private	Type Subsidiary	Type Private
Tags	Tags Business Products & Services conglomerates consumer electronics distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Manufacturing & Industrial distribution drug development pharma	Tags Healthcare distribution drug development pharma
Locations	Locations HQ	Locations Ahmedabad, IN HQ Rio De Janeiro, BR Nanterre, FR Ahmedabad, IN Ambernath, IN Ankleshwar, IN Bengaluru, IN see more	Locations Λεμεσός, CY HQ Ben Aknoun, DZ Amman, JO Rīga, LV Chișinău, MD Moscow, RU	Locations New York, US HQ	Locations ID HQ
Employees	Employees N/A	Employees 27,9176% increase	Employees 825	Employees 2,637	Employees 9272% increase
Financial
Revenue (est.)	Revenue (est.) ₩12.6b (FY, 2023)	Revenue (est.) ₹267.2b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ₩11.5b (FY, 2023)	Cost of goods ₹72.9b (FY, 2026)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ₩1.2b (FY, 2023)	Gross profit ₹203.7b (FY, 2026)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ₩903.9m (FY, 2023)	Net income ₹50.3b (FY, 2026)	Net income N/A	Net income N/A	Net income N/A